|
|||||
|
|
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions |
|
| Authors: | Alberto Ocañ a,Eitan Amir |
| Affiliation: | 1. Drug Development Program, Princess Margaret Hospital, Toronto, Canada;2. Albacete University Hospital and AECC unit, Albacete, Spain;3. Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada |
| Abstract: | |
| Keywords: | Breast cancer HER2 Irreversible tyrosine kinase inhibitors Neratinib Lapatinib Trastuzumab |
| 本文献已被 ScienceDirect 等数据库收录！ | |